Wedbush Upgrades Meridian Biosciences (VIVO) to Neutral Post Q3 Whiff & Selloff

Article Stock Quotes (1) Comments (0)

Wedbush upgraded Meridian Biosciences (NASDAQ: VIVO) from Underperform to Neutral with a price target of $17.00.

Analyst, Zarak Khurshid, said, "3Q12 results miss consensus revenue and our Street-low estimate badly...Slower C.diff, H.pylori, and Foodborne sales drove the miss...Illumigene not too bad, in our view. System placements just below our
estimates, while utilization appears fairly stable...GMs very impressive. Up 290 bps q/q despite sales falloff. Opex leaner too...Upgrading to NEUTRAL on more reasonable valuation, lowered guidance and improving profitability."

Lowers FY12 EPS estimate from $0.81 to $0.80, but raises FY13 from $0.90 to $0.94.

For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.

Shares of Meridian Biosciences closed at $16.70 yesterday, with a 52 week range of $14.81-$22.06.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• Jefferies Upgrades DDR Corp. (DDR) to Buy
• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold

Create E-mail Alert Related Categories

Analyst EPS Change, Analyst EPS View, Upgrades

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?